Entero Therapeutics (ENTO) Competitors $0.67 -0.01 (-1.46%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsShort InterestTrends ENTO vs. ORGS, MBRX, PRTG, CDIO, CELZ, SHPH, JAGX, BCDA, IMCC, and ENSCShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Orgenesis (ORGS), Moleculin Biotech (MBRX), Portage Biotech (PRTG), Cardio Diagnostics (CDIO), Creative Medical Technology (CELZ), Shuttle Pharmaceuticals (SHPH), Jaguar Health (JAGX), BioCardia (BCDA), IM Cannabis (IMCC), and Ensysce Biosciences (ENSC). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. Orgenesis Moleculin Biotech Portage Biotech Cardio Diagnostics Creative Medical Technology Shuttle Pharmaceuticals Jaguar Health BioCardia IM Cannabis Ensysce Biosciences Orgenesis (NASDAQ:ORGS) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings. Does the media favor ORGS or ENTO? In the previous week, Orgenesis had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 1 mentions for Orgenesis and 0 mentions for Entero Therapeutics. Orgenesis' average media sentiment score of 0.21 beat Entero Therapeutics' score of 0.00 indicating that Orgenesis is being referred to more favorably in the media. Company Overall Sentiment Orgenesis Neutral Entero Therapeutics Neutral Do analysts rate ORGS or ENTO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AEntero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community believe in ORGS or ENTO? Orgenesis received 1 more outperform votes than Entero Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformOrgenesisOutperform Votes1100.00% Underperform VotesNo VotesEntero TherapeuticsN/AN/A Which has better earnings and valuation, ORGS or ENTO? Entero Therapeutics has lower revenue, but higher earnings than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrgenesis$662K8.70-$55.36MN/AN/AEntero TherapeuticsN/AN/A-$15.80MN/AN/A Is ORGS or ENTO more profitable? Entero Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -6,857.25%. Orgenesis' return on equity of 0.00% beat Entero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Orgenesis-6,857.25% N/A -190.67% Entero Therapeutics N/A -119.95%-20.30% Which has more volatility and risk, ORGS or ENTO? Orgenesis has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Entero Therapeutics has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Do insiders & institutionals believe in ORGS or ENTO? 22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by insiders. Comparatively, 0.5% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryOrgenesis beats Entero Therapeutics on 8 of the 11 factors compared between the two stocks. Ad Porter & CompanyElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration. Watch this new documentary and you’ll discover what Elon knows, Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.21M$6.75B$5.04B$8.43BDividend YieldN/A7.94%7.52%4.16%P/E RatioN/A12.17130.2316.67Price / SalesN/A270.431,720.2276.26Price / CashN/A46.0936.9133.54Price / Book0.295.284.604.98Net Income-$15.80M$151.33M$114.94M$224.26M7 Day Performance16.46%0.30%0.14%1.65%1 Month Performance12.42%14.88%10.15%6.92%1 Year PerformanceN/A36.87%33.87%26.46% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero Therapeutics0.2311 of 5 stars$0.67-1.5%N/AN/A$3.21MN/A0.009Upcoming EarningsORGSOrgenesis2.7306 of 5 stars$1.23+5.2%N/AN/A$5.88M$662,000.000.00150Upcoming EarningsNews CoverageGap UpMBRXMoleculin Biotech1.8857 of 5 stars$2.52-3.8%$35.00+1,288.9%-68.0%$5.83MN/A0.0020Upcoming EarningsPositive NewsPRTGPortage Biotech1.6299 of 5 stars$5.55-6.7%$120.00+2,062.2%-85.8%$5.82MN/A-0.126Positive NewsCDIOCardio Diagnostics3.0907 of 5 stars$0.25-3.8%$2.00+691.5%-30.6%$5.73M$39,138.000.007Upcoming EarningsGap DownCELZCreative Medical Technology1.2619 of 5 stars$4.23+10.4%N/A-13.5%$5.70M$17,000.00-1.045Gap UpHigh Trading VolumeSHPHShuttle Pharmaceuticals1.3318 of 5 stars$1.80flatN/AN/A$5.31MN/A-0.525Upcoming EarningsGap DownHigh Trading VolumeJAGXJaguar Health0.7706 of 5 stars$1.06-1.9%N/A-94.5%$5.20M$10.19M0.0050Positive NewsBCDABioCardia2.5744 of 5 stars$2.37-2.1%$25.00+954.9%-60.2%$5.03M$428,000.00-0.4416Gap UpIMCCIM Cannabis0.3683 of 5 stars$2.17flatN/A-30.3%$4.84M$49.88M-0.57340Upcoming EarningsENSCEnsysce Biosciences1.0102 of 5 stars$0.64+52.6%N/A-34.3%$4.84M$2.23M-0.2310Gap UpHigh Trading Volume Related Companies and Tools Related Companies Orgenesis Competitors Moleculin Biotech Competitors Portage Biotech Competitors Cardio Diagnostics Competitors Creative Medical Technology Competitors Shuttle Pharmaceuticals Competitors Jaguar Health Competitors BioCardia Competitors IM Cannabis Competitors Ensysce Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENTO) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENTO Stock Alerts